In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid-19, the FDA said its policy will compel generation of more evidence for these groups. Our roundup of regulatory news includes notable firsts for Alzheimer’s diagnosis and migraine treatment.
The post New FDA Covid-19 Policy Supports Vaccines for High-Risk Groups, More Clinical Trials for Others appeared first on MedCity News.
